MaxWell Biosystems will showcase how high-density microelectrode arrays (HD-MEAs) can help bridge the gap in functional insights for human neural organoids and assembloids at the 29th Annual Meeting of the Korean Society for Brain and Neural Sciences (K-Brain 2026)
Published
Signal category
Presence & Recognition
Quote
“At the 29th Annual Meeting of the Korean Society for Brain and Neural Sciences (K-Brain 2026), our team will showcase how high-density microelectrode arrays (HD-MEAs) can help bridge this gap”
— MaxWell Biosystems team
Company
MaxWell Biosystems
Every Cell Has A Story To Tell. Connect to your cells and track their activity, connectivity and maturity.
- Industry
- Biotechnology Research
- Location
- Zurich, CH
- Company size
- 49 employees
Founded in September 2016 as an ETH Zürich spin-off, MaxWell Biosystems is a technology leader providing instrumentation and solutions to boost scientific research and development in neurosciences, stem cell and tissue engineering, ophthalmology, and other fields involving electrogenic cells. MaxOne (single-well) and MaxTwo (multi-well) are easy-to-use systems that equip scientists with the ability to record electrical signals of neurons in in-vitro 2D and 3D models at network, cellular, and subcellular levels. MaxWell Biosystems’ main goal is to be a trusted partner to all users and collaborators, for a greater cause, of advancing scientific breakthroughs and for achieving faster and more effective drug discovery, through our products, solutions, and expertise.
Founded 2016